Cargando…

Assessment of the clinical and analytical performance of the Aptima SARS-CoV-2 assay using the VALCOR protocol

BACKGROUND: The COVID-19 pandemic highlighted the importance of diagnostic testing against curbing the spread of SARS-CoV-2. The urgent need and scale for diagnostic tools resulted in manufacturers of SARS-CoV-2 assays receiving emergency authorization that lacked robust analytical or clinical evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhillon, Sharonjit K., Simoens, Cindy, Cuypers, Lize, Bode, Jannes, Bonde, Jesper, Corbisier, Philippe, Cocuzza, Clementina E., Van Ranst, Marc, Arbyn, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951132/ https://www.ncbi.nlm.nih.gov/pubmed/36829164 http://dx.doi.org/10.1186/s12985-023-01986-4

Ejemplares similares

VALCOR: a protocol for the validation of SARS-corona virus-2 assays
por: Arbyn, Marc, et al.
Publicado: (2022)

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework
por: Dhillon, Sharonjit K., et al.
Publicado: (2021)

Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT‐2 framework
por: Dhillon, Sharonjit K., et al.
Publicado: (2022)

Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study
por: Preisler, Sarah, et al.
Publicado: (2016)

Evaluation of Aptima Zika Virus Assay
por: Ren, Ping, et al.
Publicado: (2017)

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework
por: Bonde, Jesper Hansen, et al.
Publicado: (2020)

Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study
por: Schwebke, Jane R., et al.
Publicado: (2020)

Towards a unified classification for human respiratory syncytial virus genotypes
por: Ramaekers, Kaat, et al.
Publicado: (2020)

Attendance at Cervical Cancer Screening and Use of Diagnostic and Therapeutic Procedures on the Uterine Cervix Assessed from Individual Health Insurance Data (Belgium, 2002-2006)
por: Arbyn, Marc, et al.
Publicado: (2014)

Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy
por: Bakkour, Sonia, et al.
Publicado: (2020)

Can HPV Selfy be considered as a clinically validated HPV test for use in cervical cancer screening?
por: Arbyn, Marc, et al.
Publicado: (2022)

Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
por: de Salazar, Adolfo, et al.
Publicado: (2019)

Identification of Acute HIV-1 Infection by Hologic Aptima HIV-1 RNA Qualitative Assay
por: Manak, Mark M., et al.
Publicado: (2017)

Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program
por: Ejegod, Ditte Møller, et al.
Publicado: (2021)

Performance Evaluation of the Aptima Assays in Comparison with the cobas 6800 Assays for the Detection of HIV-1, HBV, and HCV in Clinical Samples
por: Park, Younhee, et al.
Publicado: (2022)

Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0
por: Hatzakis, Angelos., et al.
Publicado: (2016)

Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens
por: Chernesky, Max, et al.
Publicado: (2017)

Analytical Performance of the RIDASCREEN(®) Hantavirus Puumala IgG/IgM ELISA Assay
por: Depypere, Melissa, et al.
Publicado: (2020)

The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies
por: Guo, Yanli, et al.
Publicado: (2014)

Evaluation of the Aptima™ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens
por: Trémeaux, Pauline, et al.
Publicado: (2020)

Validation of an Aptima-format Finnish new variant of Chlamydia trachomatis (FI-nvCT) surveillance assay, 2019
por: Weinbaum, Barbara, et al.
Publicado: (2020)

Assessment of the Performance of the Aptima Bacterial Vaginosis Assay Over a 3-Month Period in a French Hospital
por: Ruffier d’Epenoux, L., et al.
Publicado: (2022)

French Prospective Clinical Evaluation of the Aptima Mycoplasma genitalium CE-IVD Assay and Macrolide Resistance Detection Using Three Distinct Assays
por: Le Roy, Chloé, et al.
Publicado: (2017)

Prevalence of new variants of Chlamydia trachomatis escaping detection by the Aptima Combo 2 assay, England, June to August 2019
por: Roberts, David J, et al.
Publicado: (2019)

Analytical characteristics and comparative evaluation of Aptima HCV quant Dx assay with the Abbott RealTime HCV assay and Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0
por: Worlock, A., et al.
Publicado: (2017)

Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study
por: Ejegod, Ditte Møller, et al.
Publicado: (2015)

A Study of Analytical and Clinical Sensitivity of Aptima SARS-CoV-2 Assay (Hologic) and Proposals of Complementary Tests for SARS-CoV-2 Detection in Low Viral Load Specimens
por: La, My-Van, et al.
Publicado: (2021)

HPV and head and neck cancers: Towards early diagnosis and prevention
por: Galati, Luisa, et al.
Publicado: (2022)

The Hologic Aptima SARS‐CoV‐2 assay enables high ratio pooling saving reagents and improving turnaround time
por: Newsom, Kimberly, et al.
Publicado: (2021)

Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples
por: Yan, Ying, et al.
Publicado: (2022)

Comparison of an in-house real-time duplex PCR assay with commercial HOLOGIC® APTIMA assays for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis in urine and extra-genital specimens
por: Venter, Johanna M. E., et al.
Publicado: (2019)

APTIMA assay on SurePath liquid-based cervical samples compared to endocervical swab samples facilitated by a real time database
por: Khader, Samer N., et al.
Publicado: (2010)

The ‘Finnish new variant of Chlamydia trachomatis’ escaping detection in the Aptima Combo 2 assay is widespread across Norway, June to August 2019
por: Johansen, Tone Bjordal, et al.
Publicado: (2019)

Role of Hologic® Panther Aptima™ SARS-CoV-2 assay in the detection of SARS-CoV-2: screening or diagnostic technique?
por: García-Salguero, Cristina, et al.
Publicado: (2023)

Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate
por: Arbyn, Marc, et al.
Publicado: (2009)

Multicenter Evaluation of Two Next-Generation HIV-1 Quantitation Assays, Aptima Quant Dx and Cobas 6800, in Comparison to the RealTime HIV-1 Reference Assay
por: Wiesmann, Frank, et al.
Publicado: (2018)

Validation of the Hologic Aptima Unisex and Multitest Specimen Collection Kits Used for Endocervical and Male Urethral Swab Specimens (Aptima Swabs) for Collection of Samples from SARS-CoV-2-Infected Patients
por: Avaniss-Aghajani, E., et al.
Publicado: (2020)

Finnish new variant of Chlamydia trachomatis escaping detection in the Aptima Combo 2 assay also present in Örebro County, Sweden, May 2019
por: Unemo, Magnus, et al.
Publicado: (2019)

Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
por: Figueiredo, Daniel, et al.
Publicado: (2023)

Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_issc42ctvbs5f335simult2ahb